China Pharmaceuticals & Healthcare Q4 2006

Published by: Business Monitor International

Published: Jan. 1, 2007 - 79 Pages

Table of Contents

Chapter 1 - Executive Summary

China Pharmaceuticals & Healthcare Industry SWOT

China Economic SWOT

China Business Environment SWOT

Chapter 2 - China: Business Environment Ranking

Table: Asia Business Environment Rankings

Business Environment Ranking

Economics - Long-Term Risk

Politics - Long-Term Risk

Regulatory Barriers

Domestic Sector Threat

Market Growth Potential

Market Size Ranking

Chapter 3 - China: Market Summary

Chapter 4 - Regulatory Regime

Intellectual Property Issues

IP Disputes

Counterfeit Activities

Pricing & Reimbursement Developments

Other Regulatory Developments

Chapter 5 - Industry Trends & Developments

Healthcare Sector

Domestic Pharmaceutical Sector

Foreign Company Activity

Acquisitions

Product Approvals

Establishment of Local Operations

Traditional Chinese Medicine

R&D Activity

Biotechology Sector

Active Pharmaceutical Ingredients

Chapter 6 - Industry Forecast Scenario

Overall Market Forecast

Table: China - Drug Market Forecasts

Key Growth Factors - Industry

Table: China - Health Expenditure Forecasts

Key Growth Factors - Macroeconomic

Table: China Macroeconomic Data And Forecast

Prescription Market Forecast

Table: China - Prescription Drug Market Forecast

OTC Market Forecast

Table: China - OTC Market Forecast Indicators

Generics and Branded Market Forecasts

China Pharmaceuticals & Healthcare Report Q3 2006

Table: China Generics and Branded Market Forecasts

Export/Import Forecasts

Table: China - Drug Export/Import Forecasts

Other Healthcare Data Forecasts

Table: China - Hospital Data Forecasts

Key Risks to BMI’s Forecast Scenario

Chapter 7 - Competitive Landscape

Table: Competitive Landscape in China

Table: China: disclosed FDI by US/European pharmaceutical firms, 2006

Chapter 8 - Company Profiles

Leading Multinational Companies

GlaxoSmithKline

Pfizer

AstraZeneca

Merck KGaA

Sanofi-Aventis

Novartis

Roche

Merck & Co

Indigenous Manufacturers

North China Pharmaceutical Corporation

Chapter 9 - China Biopharmaceuticals Holdings (CBH)

Chapter 10 - Aida Pharmaceutical Holdings

Chapter 11 - BMI Forecast Modelling

How We Generate Our Industry Forecasts

Technical Process

Pharmaceutical Industry

Sources

Chapter 12 - Appendix: Regional Demographic Data

Table- Manufacturing Wages (ave. per annum), US$

Table - Population

Household Spending Per Capita, US$

Private Consumption Per Capita, US$ PPP

Market Size, GDP, US$bn

Chapter 13 - Country Snapshot: China Demographic Data

Section 1: Population:

Table: Demographic Indicators (2005)

Table: Rural/Urban Breakdown

Section 2: Education & Healthcare

Table: Education

Abstract

The long-term potential of the Chinese pharmaceutical market is huge, given its large population, healthcare system modernisation and economic development. At present, prescription drugs account for just under 80% of the total market, although over-the-counter (OTC) products are slowly making inroads. At two-thirds of the market by value, generics will continue to dwarf the branded sector, although lax intellectual property (IP) regime will continue to promote the production and use of unauthorised copy drugs. China is both a large importer and exporter of medicines, especially of active pharmaceutical ingredients (APIs), with both segments set to grow rapidly over the coming years.

BMI expects the pharmaceutical market to grow 13% in 2006, with sales exceeding US$46.6bn by 2010. OTCs are likely to be the fastest growing segment, almost tripling in 2010 from US$5.2bn in 2005. In terms of prescription medicines, demographic changes will particularly boost the use of novel drugs for cardiovascular, neurological, cancer and antiviral indications that are not treated effectively by currently available therapies, as well as new versions of existing prescription antihistamines, analgesics, anti-fungal agents, cholesterol reducers and acid reducers. Ethical drugs will benefit from the expansion of the retail channels, which are presently largely limited to hospitals.

In regional terms, China will continue to outperform a number of its neighbours, but remain behind Asia's largest market, Japan. Its ongoing industrial development, improving political openness and infrastructural modifications will serve to environment may, however, should hinder pharmaceutical sector growth over the coming years. BMI's revised Business Environment Rankings for Asia place China fifth out of the 14 major markets.

The Chinese government continues to cut the price of drugs, with cancer products affected most recently. Additionally, the authorities are considering introducing price caps for all prescription drugs in the near future, which would have a negative impact on pharmaceutical revenues across the board. On the positive side, however, in a milestone ruling, the state legislature recently upheld a patent for Pfizer's erectile dysfunction drug Viagra, overturning a previous decision by patent office SIPO. While the volume of fake drugs continues to be problematic, foreign direct investment (FDI) in the Chinese armaceutical sector will grow, following gradual legal and pricing regime improvements.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.